ADAC Laboratories Introduces New, Faster PET Imaging System; Company Also Announces Technology Breakthrough for Future PET Systems.Business Editors and Health/Medical/High-Tech Writers ST. LOUIS--(BW HealthWire)--June 5, 2000 ADAC ADAC Allgemeiner Deutscher Automobil Club (German automobile club) ADAC Aboriginal Drug and Alcohol Council ADAC Art Directors and Artists Club (Sacramento, California) ADAC Alcohol and Drug Abuse Council Laboratories (Nasdaq:ADAC) today introduced at the Society of Nuclear Medicine's Annual Meeting the C-PET Plus(TM), the company's newest positron emission tomography positron emission tomography: see PET scan. positron emission tomography (PET) Imaging technique used in diagnosis and biomedical research. (PET) scanner. C-PET Plus includes faster computing hardware than the current C-PET(TM) system, as well as new software algorithms that reduce imaging times and improve overall image quality. ADAC also announced a technical breakthrough that establishes the feasibility of using Gadolinium gadolinium (gădəlĭn`ēəm), metallic chemical element; symbol Gd; at. no. 64; at. wt. 157.25; m.p. 1,312°C;; b.p. 3,233°C;; sp. gr. 7.898 at 25°C;; valence +3. Oxyortho Silicate silicate, chemical compound containing silicon, oxygen, and one or more metals, e.g., aluminum, barium, beryllium, calcium, iron, magnesium, manganese, potassium, sodium, or zirconium. Silicates may be considered chemically as salts of the various silicic acids. (GSO GSO abbr. general staff officer ) for PET imaging applications. GSO has the potential to provide very high performance capabilities useful in clinical and research applications and is currently a works in process. C-PET Plus C-PET Plus represents the next generation of ADAC's leading C-PET platform. The C-PET Plus is ideally suited for clinical applications because of its lower installation and operating costs operating costs npl → gastos mpl operacionales and faster imaging capabilities relative to competitive products. The new features in C-PET Plus will enhance throughput and image quality and, as a result, provide improved clinical and economic value. Gary Burbach, president of ADAC Medical Systems, said, "We are excited about the C-PET Plus and believe it will further advance our leadership position in the clinical PET market. Our momentum is very strong as we are benefiting from a strong product portfolio in a rapidly growing market. We expect our PET order rate in fiscal 2000 to be up four-fold versus last year." Shipments of C-PET Plus will begin in July 2000. ADAC's Newest Innovation: GSO GSO is a new crystal material that enables even higher resolution imaging than is possible with current PET technology. GSO is able to detect a broad range of isotopes An isotope a type of neutral atom but the number of neutrons is different from the number of protons in the nucleus. May be radioactive. Elements 1-15 Hydrogen
Mr. Burbach continued, "Reaching our goal of dominant leadership in all segments of the PET imaging marketplace will require clear technological superiority. The introduction of the C-PET Plus, as well as establishing the technical feasibility of GSO clearly indicate our progress toward this bold objective." About ADAC Laboratories ADAC Laboratories is the world market-share leader in nuclear medicine and radiation therapy planning systems See spreadsheet and financial planning system. , and a technology leader in providing clinical workflow solutions, management information and knowledge systems to healthcare organizations in North America North America, third largest continent (1990 est. pop. 365,000,000), c.9,400,000 sq mi (24,346,000 sq km), the northern of the two continents of the Western Hemisphere. . ADAC is headquartered in Milpitas, CA, and its HealthCare Information Systems Division is located in Houston, TX. Additional information about ADAC can be found on its web site at www.adaclabs.com This press release contains forward-looking statements forward-looking statement A projected financial statement based on management expectations. A forward-looking statement involves risks with regard to the accuracy of assumptions underlying the projections. , including statements regarding the company's product leadership and the potential market for the company's products. Factors that could cause actual results to differ materially from those in such forward-looking statements include, but are not limited to, the existence of significant competition in the markets served by the company; the company's dependence on successfully developing and marketing new products; and other factors as described in the "Business Considerations" section of the company's most recent Forms 10-K and 10-Q. All forward-looking statements are based on information available to the company on the date hereof, and the company assumes no obligation to update such statements. Note to Editors: C-PET Plus and C-PET are trademarks of ADAC Laboratories. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion